期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

他莫昔芬诱发非酒精性脂肪性肝病的研究进展 被引量：2

Research progress on nonalcoholic fatty liver disease induced by tamoxifen
原文传递
导出
摘要 他莫昔芬是一种广泛应用于治疗激素敏感型乳腺癌的抗雌激素类药物。临床研究和动物实验已经证实他莫昔芬可以诱发非酒精性脂肪性肝病(NALFD)。目前认为他莫昔芬诱发NALFD的机制主要包括脂肪酸的合成、脂肪酸的β氧化、三酰甘油转运异常以及雌激素拮抗作用。对他莫昔芬诱发NAFLD及其发病机制的研究现状进行了综述。 Tamoxifen is an anti-estrogen drug widely used for the treatment of hormone-sensitive breast cancer. Clinical research and animal studies have confirmed that tamoxifen can induce nonalcoholic fatty liver disease（NALFD）. So far, the pathogenesis of NALFD induced by tamoxifen include synthesis of aliphatic acid, β-oxidation of aliphatic acid, abnormal export of triacylglycerol, and inhibition of estrogens. The NAFLD induced by tamoxifen and its pathogenesis are reviewed in this paper.
作者 赵斐 展玉涛
机构地区 首都医科大学附属北京同仁医院消化科 北京大学首钢医院超声医学科
出处 《现代药物与临床》 CAS 2015年第8期1041-1045,共5页 Drugs & Clinic
基金 北京市教育委员会科技发展计划面上项目(KM201510025017)
关键词 他莫昔芬 非酒精性脂肪性肝病 发病机制 tamoxifen nonalcoholic fatty liver disease pathogenesis
分类号 R977.1 [医药卫生—药品] R979.1 [医药卫生—药品]
  • 相关文献

参考文献34

  • 1Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations[J].Ann Oncol, 2012, 23(suppl 6): vi7-vi12.
  • 2Harrell J C, Dye W W, Harvell D M, et al. Estrogen insensitivity in a model of estrogen receptor-positive breast cancer lymph node metastasis[J].Cancer Res, 2007, 67(21): 10582-10591.
  • 3Tomao F, Spinelli G, Vici P, et al. Current role and safety profile of aromatase inhibitors in early breast cancer[J].Expert Rev Anticancer Ther, 2011, 11(8): 1253-1263.
  • 4Lee M H, Kim J W, Kim J H, et al. Gene expression profiling of murine hepatic steatosis induced by tamoxifen[J].Toxicol Lett, 2010, 199(3): 416-424.
  • 5Cole L K, Jacobs R L, Vance D E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis[J].Hepatology, 2010, 52(4): 1258-1265.
  • 6Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial[J].BMJ, 2005, 330(7497): 932.
  • 7Akhondi-Meybodi M, Mortazavy-Zadah M R, Hashemian Z, et al. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer[J].Arab J Gastroenterol, 2011, 12(1): 34-36.
  • 8Saphner T, Triest-Robertson S, Li H, et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer[J].Cancer, 2009, 115(14): 3189-3195.
  • 9Nishino M, Hayakawa K, Nakamura Y, et al. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy[J].AJR Am J Roentgenol, 2003, 180(1): 129-134.
  • 10张培宇.乳腺癌患者非医嘱停用三苯氧胺原因及中药疗效[J].中国中西医结合外科杂志,2005,11(6):493-494. 被引量：19

二级参考文献18

  • 1Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1513
  • 2西原利治,路晓阳.药物诱发性NASH[J].日本医学介绍,2007,28(4):159-161. 被引量：5
  • 3Mizuki N, Katsumi H, Yoshiaki N, et al. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy[J]. Am J Roentgenol, 2003, 180(1): 129-134.
  • 4Egawa T, Toda K, Nemoto Y, et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice [J]. Lipids, 2003, 38(5): 519-523.
  • 5Lelliott C J, Lopez M, Curtis R K, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis[J]. FASEB J, 2005, 19(9): 1108-1119.
  • 6Oddrun A G, Therese H R, Rolf K B. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver [Jl. J Lipid Res, 2006, 47(10): 2223-2232.
  • 7Coskun U, Toruner F B, Gunel N. Tamoxifen therapy and hepatic steatosis [J].Neoplasma, 2002, 49(1) : 61-64.
  • 8Saphner T, Triest-Robertson S, Li H, et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer[J].Cancer, 2009, 115(14) : 3189-3195.
  • 9Mizuki N, Katsumi H, Yoshiaki N, et al. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy [J]. AJR, 2003, 180(1): 129-134.
  • 10Marian J.E.,Mounts MD,Elisabeth G.E,Tamoxifen treatment and gynecologic side effects:A review [J].Obstetrics & Gynecology,2001,97:855.

共引文献338

同被引文献47

引证文献2

二级引证文献6

现代药物与临床
2015年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部